CYTOKINETICS INCORPORATED - COMMON STOCK

NetDania - New 12 months Low: CYTOKINETICS INCORPORATED - COMMON STOCK

11 2 2025 14:34:09 提供 NetDania Notify

Cytokinetics Names Robert E. Landry to Board of Directors

11 2 2025 07:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: CYTOKINETICS INCORPORATED - COMMON STOCK

10 2 2025 09:56:36 提供 NetDania Notify

NetDania - New 12 months Low: CYTOKINETICS INCORPORATED - COMMON STOCK

07 2 2025 10:17:25 提供 NetDania Notify

Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

05 2 2025 16:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 2 2025 16:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program

30 1 2025 07:30:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

21 1 2025 07:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: CYTOKINETICS INCORPORATED - COMMON STOCK

13 1 2025 14:43:22 提供 NetDania Notify

Cytokinetics Announces 2025 Corporate Milestones and Vision 2030

13 1 2025 07:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: CYTOKINETICS INCORPORATED - COMMON STOCK

10 1 2025 10:28:43 提供 NetDania Notify

Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 1 2025 16:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

03 1 2025 16:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

23 12 2024 07:30:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

20 12 2024 00:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 12 2024 16:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction

03 12 2024 07:30:00 提供 Nasdaq GlobeNewswire

Cytokinetics to Participate in December Investor Conferences

02 12 2024 16:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

02 12 2024 07:30:00 提供 Nasdaq GlobeNewswire

Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan

19 11 2024 02:30:00 提供 Nasdaq GlobeNewswire